search
Back to results

FMT for Post-infectious IBS

Primary Purpose

Irritable Bowel Syndrome

Status
Completed
Phase
Not Applicable
Locations
Ukraine
Study Type
Interventional
Intervention
Fecal transplantation
OTILONII BROMIDUM
multi-strain probiotic
Sponsored by
Bogomolets National Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Irritable Bowel Syndrome focused on measuring Irritable Bowel Syndrome, fecal microbiota transplantation, postinfectious irritable bowel syndrome

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  • age 18-65 years
  • PI-IBS diagnosis in accordance with the Rome IV criteria
  • moderate-severe disease activity (as determined by an IBS-Symptom Severity Score ≥175)
  • normal appearing colon on colonoscopy with biopsy that did not reveal pathology
  • signed inform consent.

Exclusion Criteria:

  • systemic disease, immunodeficiency, or previous treatment with immunomodulators;
  • pregnant or breastfeeding;
  • previous surgery on the abdominal cavity, with the exception of appendectomy, cholecystectomy, caesarean section and hysterectomy;
  • severe current disease (hepatic, renal, respiratory, or cardiovascular);
  • probiotic or antibiotic use within 8 weeks prior to study initiation;
  • any condition or circumstance that would, in the opinion of the investigator, prevent completion of the study or interfere with analysis of study results.

Sites / Locations

  • Bogomolets National Medical University
  • Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Fecal transplantation group

Standard-care group

Arm Description

Fecal transplantation of frozen prepared feces from healthy donor. Application by colonoscope in proximal half of colon.

FODMAP diet, Otilonium Bromide, oral, (40mg, 1 tablet TID) and a multi-strain probiotic, oral, (1 capsule BID)

Outcomes

Primary Outcome Measures

Change in Irritable bowel syndrome severity scoring system (IBS-SSS)
This questionnaire contains five questions, each with a maximum score of 100 using a visual analog scale. Total scores between 75 and 175 were considered indicative of mild IBS severity, 175-300 were moderate, and >300 were severe.
assesment of response rate
response rate was assessed as decrease of ≥ 50 points on the IBS-SSS

Secondary Outcome Measures

Change in BS Quality of Life Scale (IBS-QoL)
This questionnaire contains 34 items concerning the physical and psychological functioning of IBS patients in 8 domains: dysphoria, activity interference, body image, health concerns, food avoidance, social reactions, sexual function and impact on relationships.
Change in Fatigue Assessment Scale (FAS)
The questionnaire comprises 10 questions with 5-point-scale answers varying from never to always. Five of these questions measured physical fatigue and the other five measured mental fatigue.
Bacteriology measured in the stool flora by specialized non-culture techniques
The percentage of patients in each group were evaluated and characterized by a decrease below the normal content of symbiotic bacteria Bifidobacterium (less than 107 CFU / g), lactobacilli (less than 107 CFU / d), E.coli with normal properties (less than 106 CFU / d) and increase in content E.coli with altered properties (more than 106 CFU / g), pathogenic enterobacteria (not normally detected) and fungi of the genus Candida (more than 104 CFU / d)
Microbiome profile change
Characterization of fecal microbiome by metagenomic analysis before and after intervention Characterization of fecal microbiome by metagenomic analysis before and after intervention

Full Information

First Posted
July 11, 2022
Last Updated
July 14, 2022
Sponsor
Bogomolets National Medical University
Collaborators
Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine
search

1. Study Identification

Unique Protocol Identification Number
NCT05461833
Brief Title
FMT for Post-infectious IBS
Official Title
Fecal Microbiota Transplantation in Patients With Post-infection Irritable Bowel Syndrome: a Randomized, Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
September 1, 2020 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
January 15, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bogomolets National Medical University
Collaborators
Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Considering that PI-IBS is brought on by infection and gut microbiota may be associated with the onset of symptoms, the modification of altered gut microbiota with nonabsorbable antibiotics such as rifaximin-α or probiotics is often employed as first-stage treatment. Research in recent years has also shown the potential benefits of fecal microbiota transplantation (FMT) for IBS, which is the replacement of a sick recipient's gut microbiota with fecal material from a healthy donor. Even though the only officially approved indication for FMT at this time is recurrent Clostridium difficile infection, the effectiveness of FMT is nevertheless being studied for the treatment of other gastrointestinal and non-gastrointestinal pathologies including IBS. To date, several controlled and uncontrolled studies have been conducted to study the effectiveness of FMT for IBS, and most of them have demonstrated positive results. The investigators have not come across studies devoted to the study of the effectiveness of FMT in patients with PI-IBS in the available literature. So, the aim of the current study was to conduct single-centre, randomized clinical trial to assess the safety, clinical and microbiological efficacy of FMT in patients with PI-IBS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Irritable Bowel Syndrome
Keywords
Irritable Bowel Syndrome, fecal microbiota transplantation, postinfectious irritable bowel syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
59 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fecal transplantation group
Arm Type
Experimental
Arm Description
Fecal transplantation of frozen prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
Arm Title
Standard-care group
Arm Type
Active Comparator
Arm Description
FODMAP diet, Otilonium Bromide, oral, (40mg, 1 tablet TID) and a multi-strain probiotic, oral, (1 capsule BID)
Intervention Type
Biological
Intervention Name(s)
Fecal transplantation
Other Intervention Name(s)
Fecal microbial transplantation
Intervention Description
Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
Intervention Type
Drug
Intervention Name(s)
OTILONII BROMIDUM
Other Intervention Name(s)
Spasmomen®
Intervention Description
OTILONII BROMIDUM , oral, 40 mg TID, 1 months of treatment
Intervention Type
Dietary Supplement
Intervention Name(s)
multi-strain probiotic
Intervention Description
multi-strain probiotic, oral, 1 capsule BID for 1 month
Primary Outcome Measure Information:
Title
Change in Irritable bowel syndrome severity scoring system (IBS-SSS)
Description
This questionnaire contains five questions, each with a maximum score of 100 using a visual analog scale. Total scores between 75 and 175 were considered indicative of mild IBS severity, 175-300 were moderate, and >300 were severe.
Time Frame
at 0, 2, 4 and 12 weeks
Title
assesment of response rate
Description
response rate was assessed as decrease of ≥ 50 points on the IBS-SSS
Time Frame
at 12 weeks
Secondary Outcome Measure Information:
Title
Change in BS Quality of Life Scale (IBS-QoL)
Description
This questionnaire contains 34 items concerning the physical and psychological functioning of IBS patients in 8 domains: dysphoria, activity interference, body image, health concerns, food avoidance, social reactions, sexual function and impact on relationships.
Time Frame
at 0, 2, 4 and 12 weeks
Title
Change in Fatigue Assessment Scale (FAS)
Description
The questionnaire comprises 10 questions with 5-point-scale answers varying from never to always. Five of these questions measured physical fatigue and the other five measured mental fatigue.
Time Frame
at 0, 2, 4 and 12 weeks
Title
Bacteriology measured in the stool flora by specialized non-culture techniques
Description
The percentage of patients in each group were evaluated and characterized by a decrease below the normal content of symbiotic bacteria Bifidobacterium (less than 107 CFU / g), lactobacilli (less than 107 CFU / d), E.coli with normal properties (less than 106 CFU / d) and increase in content E.coli with altered properties (more than 106 CFU / g), pathogenic enterobacteria (not normally detected) and fungi of the genus Candida (more than 104 CFU / d)
Time Frame
at 0 and 1 months
Title
Microbiome profile change
Description
Characterization of fecal microbiome by metagenomic analysis before and after intervention Characterization of fecal microbiome by metagenomic analysis before and after intervention
Time Frame
at 0 and 1 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria age 18-65 years PI-IBS diagnosis in accordance with the Rome IV criteria moderate-severe disease activity (as determined by an IBS-Symptom Severity Score ≥175) normal appearing colon on colonoscopy with biopsy that did not reveal pathology signed inform consent. Exclusion Criteria: systemic disease, immunodeficiency, or previous treatment with immunomodulators; pregnant or breastfeeding; previous surgery on the abdominal cavity, with the exception of appendectomy, cholecystectomy, caesarean section and hysterectomy; severe current disease (hepatic, renal, respiratory, or cardiovascular); probiotic or antibiotic use within 8 weeks prior to study initiation; any condition or circumstance that would, in the opinion of the investigator, prevent completion of the study or interfere with analysis of study results.
Facility Information:
Facility Name
Bogomolets National Medical University
City
Kyiv
ZIP/Postal Code
01601
Country
Ukraine
Facility Name
Ukrainian Research and Practical Centre of Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Health of Ukraine
City
Kyiv
Country
Ukraine

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

FMT for Post-infectious IBS

We'll reach out to this number within 24 hrs